申请人:GLAXO GROUP LIMITED
公开号:EP0429257A2
公开(公告)日:1991-05-29
The invention provides compounds of the general formula (I):
or a physiologically acceptable salt or a solvate (e.g. hydrates) thereof in which
R¹ represents a hydrogen atom or a halogen atom or a group selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, fluoroC₁₋₆alkyl, -CHO, -CO₂H or -COR⁴;
R² represents a hydrogen atom or a halogen atom or the group Ar;
R³ represents a hydrogen atom or a group selected from C₁₋₆ alkyl, C₃₋₆alkenyl, C₁₋₆alkoxy, -COR⁴, -SO₂R⁴ or the group Ar;
R⁴ represents a group selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ alkoxy or the group -NR¹²R¹³;
Ar represents the group
R⁵ represents a group selected from -CO₂H, -NHSO₂CF₃ or a C-linked tetrazolyl group;
R⁶ and R⁷ which may be the same or different each independently represent a hydrogen atom or a halogen atom or a C₁₋₆alkyl group;
Het represents an N-linked imidazolyl group substituted at the 2-position by a C₁₋₆alkyl, C₂₋₆alkenyl or a C₁₋₆alkylthio group, the imidazolyl group optionally being substituted by one or two further substituents selected from a halogen atom or a group selected from cyano, nitro, C₁₋₆alkyl, C₂₋₆alkenyl, fluoroC₁₋₆alkyl, -(CH₂)mR⁸, -(CH₂)nCOR⁹, or -(CH₂)pNR¹⁰COR¹¹;
or Het represents an N-linked benzimidazolyl group substituted at the 2-position by a C₁₋₆alkyl, C₂₋₆alkenyl or a C₁₋₆alkylthio group;
R⁸ represents a hydroxy or C₁₋₆alkoxy group;
R⁹ represents a hydrogen atom or a group selected from hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, phenyl, phenoxy or the group -NR¹²R¹³;
R¹⁰ represents a hydrogen atom or a C₁₋₆alkyl group;
R¹¹ represents a hydrogen atom or a group selected from C₁₋₆alkyl, C₁₋₆alkoxy, phenyl, phenoxy or the group -NR¹²R¹³;
R¹² and R¹³ which may be the same or different each independently represent a hydrogen atom or a C₁₋₄alkyl group or -NR¹²R¹³ forms a saturated heterocyclic ring which has 5 or 6 ring members and may optionally contain in the ring one oxygen atom;
m represents an integer from 1 to 4;
n represents an integer from 0 to 4; and
p represents an integer from 1 to 4;
provided that one of R² and R³ represents the group Ar, and that when R² represents the group Ar, R³ represents a hydrogen atom or a group selected from C₁₋₆ alkyl, C₃₋₆ alkenyl, C₁₋₆alkoxy -COR⁴ or -SO₂R⁴, and that when R³ represents the group Ar, R² represents a hydrogen atom or a halogen atom.
The compounds may be used in the treatment or prophylaxis of hypertension and diseases associated with cognitive disorders.
本发明提供通式 (I) 的化合物:
或其生理上可接受的盐或溶液(如
水合物),其中
R¹ 代表氢原子或卤原子或选自 C₁₋₆ 烷基、C₂₋₆ 烯基、
芴基、-CHO、-CO₂H 或 -COR⁴ 的基团;
R² 代表氢原子、卤素原子或基团 Ar;
R³ 代表氢原子或选自 C₁₋₆83↩₋₆ 烷基、C₁₋₆烷氧基、-COR⁴、-SO₂R⁴ 或基团 Ar 的基团;
R⁴ 代表选自 C₁₋₆ 烷基、C₂₋₆ 烯基、C₁₋₆ 烷氧基或基团 -NR¹²R¹³ 的基团;
Ar 代表以下基团
R⁵ 代表选自 -CO₂H、-NHSO₂CF₃ 或 C-链锁
四唑基的基团;
R⁶ 和 R⁷ 可以相同或不同,各自独立地代表氢原子、卤素原子或 C₁₋₆ 烷基;
Het 代表在 2 位被 C₁₋₆烷基、C₂₋₆烯基或 C₁₋₆ 烷
硫基取代的 N-连接的
咪唑基、
咪唑基可任选被一个或两个取代基取代,这两个取代基可选自卤素原子或选自
氰基、硝基、C烷基
硫代、C烷基
硫代、C烷基
硫代或C烷基
硫代的基团、硝基、C₂₋₆烷基、
芴基、-(CH₂)mR⁸、-(CH₂)nCOR⁹或-(CH₂)pNR¹⁰COR¹;
或 Het 代表在 2 位被 C₁₋₆烷基、C₂₋₆烯基或 C₁₋₆ 烷
硫基取代的 N-连接的
苯并咪唑基团;
R⁸ 代表羟基或 C₁₋₆ 烷氧基;
R⁹ 代表氢原子或选自羟基、C₁₋₆烷基、C₁₋₆烷氧基、苯基、苯氧基或基团 -NR¹²R¹³ 的基团;
R¹⁰ 代表氢原子或 C₁₋₆ 烷基;
R¹¹ 代表氢原子或选自 C₁₋₆烷基、C₁₋₆烷氧基、苯基、苯氧基或基团 -NR¹²R¹³ 的基团;
R¹² 和 R¹³ 可以相同或不同,各自独立地代表氢原子或 C₁₋₄烷基或 -NR¹²R¹³ 形成饱和杂环,该杂环有 5 或 6 个环成员,环中可选择包含一个氧原子;
m 代表 1 至 4 的整数;
n 代表 0 至 4 的整数;以及
p 代表 1 至 4 的整数;
条件是 R² 和 R³ 中的一个代表基团 Ar,且当 R² 代表基团 Ar 时,R³ 代表氢原子或选自 C₁₋₆ 烷基的基团、C₃₋₆烯基、C₁₋₆烷氧基-COR⁴或-SO₂R⁴,当 R³ 代表基团 Ar 时,R² 代表氢原子或卤素原子。
这些化合物可用于治疗或预防高血压和与认知障碍有关的疾病。